Despite its relevance to prognosis and treatment response, baseline disease duration is inconsistently reported in phase 3 clinical trials for chronic spontaneous urticaria (CSU), ...

Improvements seen across all six DLQI Domains indicating broad, beneficial impact on quality of life -- Data further demonstrates ...

Celldex (NASDAQ:CLDX) presented additional positive data from the completed Phase 2 clinical trials of barzolvolimab in ...

The authors noted that both chronic urticaria and IBS are primarily clinical diagnoses rather than conditions confirmed by ...

Dupixent drives a larger share of Sanofi's revenue, with atopic dermatitis, asthma, and CRSwNP as core indications. Learn ...

Patients maintain their improvements off treatment, even after clearance of barzolvolimab, investigators report.

Detailed price information for Celldex Therapeutics (CLDX-Q) from The Globe and Mail including charting and trades.

Septerna has reported positive past Phase 1 results for SEP-631, an oral negative allosteric modulator of MRGPRX2, showing robust target engagement, functional pathway blockade, and tolerability ...

SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as 10 mg Once-Daily Well-Tolerated Across All Doses ...

Detailed price information for Celldex Therapeutics (CLDX-Q) from The Globe and Mail including charting and trades.

Supplemental regulatory filings are underway following positive results for remibrutinib in treating symptomatic dermographism. Topline results were announced from a phase 3 trial evaluating ...

William Truswell, MD, FACS, operates his own cosmetic and reconstructive facial surgery practice. Dr. Truswell was the first in his area in Western Massachusetts to have an accredited private office ...